Unlock Premium Data: Up to 50% Off InvestingProCLAIM SALE

Provention prices diabetes drug above analysts' estimates at $13,850/vial

Published 11/18/2022, 08:59 AM
Updated 11/18/2022, 05:55 PM
© Reuters.

By Raghav Mahobe and Nandhini Srinivasan

(Reuters) -Provention Bio Inc has priced its diabetes drug teplizumab at $13,850 a vial, it said on Friday, a day after receiving U.S. approval and far higher than some analysts' expectations.

The company's shares reversed course from premarket gains to trade down nearly 12% as the high pricing stoked fears over insurance coverage.

The U.S. Food and Drug Administration on Thursday approved use of the drug for patients, with stage 2 of type 1 diabetes, to delay the onset of insulin dependence in those aged 8 years and above.

A 14-day regimen, or a course of the drug would translate to a wholesale price of $193,900, the company said on a conference call. The wholesale price is not necessarily what patients pay for a drug.

"This (price) is much higher than perhaps what the Street was expecting," said Gregory Renza, an analyst at RBC Capital Markets.

"Investors will have some level of concern that this pricing could lead to insurance hurdles," said SMBC Nikko Securities analyst David Hoang, who was expecting the treatment to cost $70,000 to $80,000 per course.

Type 1 diabetes is an autoimmune disease caused by the destruction of beta cells in the pancreas that produce insulin.

More than 1.8 million people in the United States suffer from type 1 diabetes, according to Provention.

In October, the company signed a co-promotion deal for the drug with Sanofi (NASDAQ:SNY), offering the French drugmaker first negotiation for exclusive global rights to commercialize the drug in exchange for an upfront payment of $20 million.

Teplizumab belongs to a class of drugs known as anti-CD3 therapies, which bind themselves to certain white blood cells to suppress the body's immune response.


Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.